ArticleTranslational cancer research2026
Prognostic value of systemic inflammation indices in patients with metastatic colorectal cancer treated with TAS-102: a single-center retrospective real-world study.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While the efficacy of trifluridine/tipiracil (TAS-102) in late-line metastatic colorectal cancer (mCRC) is established in clinical trials, real-world predictive and prognostic factors remain poorly characterized. This study aimed to identify these factors in mCRC patients receiving TAS-102 at The Second Affiliated Hospital of Anhui Medical University. Methods: Data were extracted from The Second Affiliated Hospital of Anhui Medical University to evaluate the clinical outcomes of microsatellite stable mCRC patients treated with TAS-102 in late-line between 2019 and 2025. Pan-immune-inflammation value (PIV), systemic immune-inflammation index (SII) values, neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) before treatment and other potential risk factors were retrospectively collected. The receiver operating characteristic curves were applied to determine the cut-off values of PIV, SII, NLR, and PLR in patients. The risk factors for progression-free survival (PFS) and overall survival (OS) were compared with Kaplan-Meier curves and determined by univariate and multivariate Cox regression analyses. Factors with P<0.05 in univariate analysis were included in multivariate analysis. Results: A total of 61 mCRC patients were enrolled. In the multivariate analysis of PFS, two favorable indices were significant: Eastern Cooperative Oncology Group Performance Status (ECOG-PS) <2 (P=0.03) and SII <650 (P=0.003). Two independent prognostic factors identified in the multivariate analysis of OS were ECOG-PS <2 (P=0.002) and NLR <2.35 (P=0.03). Conclusions: Our findings demonstrate that pretreatment inflammatory indices (NLR and SII) combined with baseline ECOG-PS independently identify mCRC patients likely to derive clinical benefit from TAS-102 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.